<DOC>
	<DOCNO>NCT01367275</DOCNO>
	<brief_summary>The goal clinical research study learn add brivanib irinotecan help control disease patient colorectal cancer spread . The safety drug combination also study .</brief_summary>
	<brief_title>Irinotecan Plus Brivanib Metastatic Colorectal Cancer ( CRC ) Enriched Elevated Levels Plasma FGF</brief_title>
	<detailed_description>Study Drugs : Brivanib design keep cancer cell receive blood supply need . This may slow growth cancer cell . Irinotecan design interfere DNA ( genetic material ) cancer cell . This may slow growth spread cancer cell . Study Drug Administration : If find eligible take part study , take brivanib mouth 1 time every day . The study drug take time day glass ( 8 ounce ) water . You take without food . You give irinotecan vein 1Â½ hour Day 1 14-day cycle . You may give drug help prevent side effect . The study staff tell drug , give , possible risk . If side effect , tell doctor study nurse right away . Your study doctor may prescribe drug side effect , delay future treatment , low dose study drug , stop treatment study drug . Study Visits : On Day 7 Cycle 1 : - Your vital sign measure . - Blood ( 2 tablespoon ) draw routine test check thyroid function . If doctor think need , part blood may use check blood 's ability clot . Before cycle , start Cycle 2 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 1-2 tablespoon ) collect routine test . If doctor think need , part blood may use check blood 's ability clot need . - You ask drug may take side effect may . - Before Cycles 2 3 , blood ( 1 tablespoon ) drawn check thyroid function . Every 8 week : - You CT scan MRI scan check status disease . - Blood ( 2-3 tablespoon ) drawn thyroid , CEA , cytokine testing . - Urine collect routine test . Every 12 week ( Weeks 12 , 24 , 36 , ) , ECHO check heart function . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . End-of-Treatment Visit : Within 2 week stop take study drug , follow test procedure perform do last 14 day : - You ask side effect may drug may take . - You physical exam , include measurement vital sign . - Your performance status record . - You CT scan MRI scan check status disease . - Blood ( 1-2 tablespoon ) urine collect routine test . - Blood ( 2-3 tablespoon ) drawn thyroid , CEA , cytokine test . Long-Term Follow-Up : After stop taking study drug , call every 3 month . You ask question health . These call last 15 minute time . This investigational study . Brivanib FDA approve commercially available . It currently use research purpose . Irinotecan FDA approve commercially available treatment colorectal cancer . The combination brivanib irinotecan consider investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Signed write Informed Consent . 2 . Patient must progress frontline chemotherapy treatment contain bevacizumab histologically confirm colorectal adenocarcinoma unresectable metastatic . Progression define either radiographic clinical progression . 3 . Patient must measurable lesion define RECIST version 1.1 criterion . 4 . ECOG performance status 02 . 5 . Known bFGF level perform CLIAcertified laboratory perform within 12 week last bevacizumab treatment 6 . Enrollment `` Assessment Targeted Therapies Against Colorectal Cancer '' ( ATTACC ) protocol 20090091 . 7 . LVEF &gt; 50 % measure 2D echocardiogram 8 . Bone marrow function define follow : An absolute neutrophil count ( ANC ) =/ &gt; 1,500/mcl ; Platelets =/ &gt; 100,000/mcl ; Hemoglobin =/ &gt; 8.5 g/dl . 9 . Renal function define follow : Serum creatinine less equal 1.5 x institutional upper limit normal ( ULN ) . 10 . Hepatic function define follow : Serum total bilirubin &lt; 1.5 x ULN ; AST ( SGOT ) , ALT ( SGPT ) alkaline phosphatase =/ &lt; 2.5 x ULN ; Serum albumin =/ &gt; 2.5 g/dl ; If liver involvement , AST , ALT , alkaline phosphatase =/ &lt; 5.0 x ULN . 11. International normalize ratio ( INR ) =/ &lt; 2.3 Prothrombin Time ( PT ) =/ &lt; 6 second control unless patient currently receive warfarin therapy treatment prevention venous thrombosis . 12 . Men woman , age =/ &gt; 18 year . 13 . A male subject father potential must use adequate method contraception avoid conception throughout study [ 12 week last dose study drug ] minimize risk pregnancy . If partner pregnant breastfeeding , subject must use condom . 14 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 12 week last dose study drug minimize risk pregnancy . WOCBP must negative serum urine pregnancy test within 72 hour start investigational product . 1 . Women pregnant breastfeeding . 2 . Patients brain metastasis . 3 . Patients resectable colorectal cancer nonadenocarcinoma cancer colon rectum . 4 . Patients prior therapy brivanib , antiPDGFR ( plateletderived growth factor receptor ) antiFGFR ( fibroblast growth factor receptor ) therapy . 5 . Recent ( within 4 week first study drug administration ) , plan participation another experimental therapeutic drug study . 6 . Recent ( within 4 week first study drug administration ) infusion bevacizumab therapy . 7 . Prior irinotecan chemotherapy . 8 . Prior full field radiotherapy =/ &lt; 4 week limited field radiotherapy =/ &lt; 2 week prior first study drug administration . 9 . Recent use ( within 4 week first study drug administration ) St. John 's Wort . 10 . Patients history thrombotic embolic event within last six month cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism . 11 . Patients gastrointestinal bleed hemorrhage/bleeding event CTCAE ( version 4.0 ) Grade 4 within 30 day prior first study drug administration 12 . Patients uncontrolled significant cardiovascular disease include : ) Active coronary artery disease , unstable newly diagnose angina myocardial infarction &lt; 12 month prior first study drug administration . ii ) Class IIIIV New York Heart Association ( NYHA ) congestive heart failure . iii ) Uncontrolled hypertension ( Systolic blood pressure [ BP ] &gt; 150 mmHg diastolic BP &gt; 90 mmHg 24 hour ) despite optimal medical management . Blood pressure must 140/90 mmHg screening . Subjects history hypertension receive treatment calcium channel blocker CYP3A4 substrates change alternative antihypertensive medication prior first study drug administration . iv ) Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . v ) QTc ( Fridericia ) prolongation &gt; 450 msec . vi ) Subjects valvular heart disease =/ &gt; CTCAE ( Ver . 4.0 ) Gr 2. vii ) Left ventricular ejection fraction ( LVEF ) &lt; 50 % . 13 . Active infection , less 7 day complete systemic antibiotic therapy . 14 . History nonhealing wound ulcer , bone fracture within 3 month prior first study drug administration . 15 . Major surgical procedure , open biopsy , significant traumatic injury le 3 week receive minor surgical procedure ( e.g . core biopsy fine needle aspiration ) within 1 week first dose first study drug administration . 16 . Inability swallow tablet untreated malabsorption syndrome . 17 . Preexisting thyroid abnormality thyroid function maintain normal range medication . 18 . History human immunodeficiency virus ( HIV ) . 19 . Patients centrally cavitating lung lesion . 20 . Known bleeding diathesis . 21 . Inability comply study and/or followup procedure . 22 . Patients know glomerular nephritis . 23 . Patients know polycythemia . 24 . Patients know Gilbert 's syndrome . 25 . Women positive pregnancy test . 26 . Patients hyponatremia ( sodium &lt; 130 mmol/L ) . 27 . Baseline serum potassium &lt; 3.5 mmol/L ( potassium supplementation may give restore serum potassium level prior study entry ) . 28 . Baseline serum calcium &lt; 8.4 mg/dL ( calcium supplementation may give restore serum calcium level prior study entry ) . 29 . Baseline serum magnesium &lt; 1.5 mg/dL ( magnesium supplementation may give restore serum magnesium level prior study entry ) . 30 . Known suspected history allergy brivanib agent give association study . 31 . Prisoners subject involuntarily incarcerate . Patients compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>colon</keyword>
	<keyword>Colorectum</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Plasma FGF</keyword>
	<keyword>Colorectal adenocarcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Brivanib</keyword>
	<keyword>BMS-582664</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Camptosar</keyword>
	<keyword>Fibroblast Growth Factor</keyword>
	<keyword>bFGF</keyword>
	<keyword>tyrosine kinase receptor</keyword>
	<keyword>vascular endothelial growth factor receptor</keyword>
	<keyword>VEGFR</keyword>
	<keyword>fibroblast growth factor receptor</keyword>
	<keyword>FGFR</keyword>
</DOC>